NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Oracle Corporation ("Oracle" or the "Company") (NYSE: ORCL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Oracle investors who were adversely affected by alleged securities fraud between June 12, 2025 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/oracle-corporation-lawsuit-su ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ardent Health, Inc. ("Ardent Health, Inc." or the "Company") (NYSE: ARDT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Ardent Health, Inc. investors who were adversely affected by alleged securities fraud between July 18, 2024 and November 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/ar ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Varonis Systems, Inc. ("Varonis" or the "Company") (NASDAQ: VRNS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Varonis investors who were adversely affected by alleged securities fraud between February 4, 2025 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/varonis-systems-inc- ...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Gemini Space Station, Inc. (Nasdaq: GEMI) for potential securities law violations. Investors who have lost money in their Gemini Space Station, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/gemi. What is this all about? Shares of Gemini Space Station fell over 10% on February 17, trading below $7 per share in intraday trading, af ...

EHAB Stock Alert: Halper Sadeh LLC is Investigating Whether Enhabit, Inc. is Obtaining a Fair Price for its Shareholders-# EHAB Stock Alert: Halper Sadeh LLC is Investigating Whether Enhabit, Inc. is Obtaining a Fair Price for its ShareholdersShare---Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transaction may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and ...

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors in Varonis Systems, Inc. (NASDAQ: VRNS) regarding the approaching March 9, 2026, lead plaintiff deadline in a pending securities class action lawsuit that has been filed against the company and certain of its executives. As alleged in the suit, the firm is examining whether Varonis executives concealed significant renewal softness within its Federal vertical and legacy on-premises busin ...

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Commvault Systems, Inc. (NASDAQ: CVLT) or its executive officers complied with the federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Commvault securities?If you purchased Commvault securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.Or for more infor ...

Core Viewpoint - A securities fraud lawsuit has been filed against Kyndryl Holdings, Inc. and certain executives following a significant drop in share price due to internal accounting issues and executive departures [1][2]. Group 1: Company Issues - Kyndryl Holdings' shares fell over 50% in intraday trading on February 9, 2026, after the company announced an internal accounting review and a delay in filing its quarterly report [2]. - The internal review focuses on cash management practices, related disclosures, and internal control over financial reporting, prompted by document requests from the SEC [2]. - Kyndryl does not expect a restatement of its financials but anticipates reporting material weaknesses in internal control over financial reporting for FY25 and the first three quarters of FY26 [2]. Group 2: Lawsuit Details - The lawsuit alleges that Kyndryl made false and misleading statements regarding its financial statements, internal controls, and the timely filing of its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025 [3]. - It is claimed that Kyndryl lacked adequate internal controls and materially understated issues related to them, leading to misleading statements about the company's business and prospects [3]. Group 3: Investor Information - Investors who purchased Kyndryl Holdings common stock between August 7, 2024, and February 9, 2026, may be eligible to participate in the lawsuit, regardless of whether they have sold their shares [4]. - The deadline to seek appointment as lead plaintiff is April 13, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about Kyndryl Holdings are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Philadelphia, Pennsylvania--(Newsfile Corp. - February 23, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Varonis Systems, Inc. (NASDAQ: VRNS) ("Varonis" or the "Company") on behalf of investors who purchased or otherwise acquired Varonis securities during the period of February 4, 2025 through October 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Varonis securities during the Class Period may, no later than M ...

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on patients and downplayed the risks associated with the Phase III Orbit study, which ultimately failed to show statistically significant results [3]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].